Vital Art and Science Gains New U.S. Patent for mVT Service

The U.S. Patent Office has awarded Vital Art and Science a new patent for its mVT Service, an FDA-cleared device that tracks disease progression in age-related macular degeneration and diabetic retinopathy patients.

The patent specifically addresses the product’s handheld visual function testing with touchscreen display, the Richardson, Texas, company said Wednesday.

The device enables patients to test their vision at home, usually conducted twice a week for four to six minutes. Results are immediately sent to a database and analyzed, the devicemaker says, adding that significant changes will initiate an alert to the prescriber.

The product was launched in April. — Jason Scott